Activation of CB receptors by the mixed CB1 and CB2 agonist—WIN 55,212-2 can significantly block the formation of new blood vessels, decrease proliferation, tumor growth and induce apoptosis of melanoma cells in the mouse exografted tumor model (Table 1). This evidence concerns the gene CNR1 and melanoma.